Hydralazine
- Generic Name
- Hydralazine
- Brand Names
- Apresoline, Bidil
- Drug Type
- Small Molecule
- Chemical Formula
- C8H8N4
- CAS Number
- 86-54-4
- Unique Ingredient Identifier
- 26NAK24LS8
- Background
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.
Hydralazine hydrochloride was FDA approved on 15 January 1953.
- Indication
Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension. A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.
- Associated Conditions
- Heart Failure, Hypertension, Essential Hypertension, Hypertensive crisis, Severe Hypertension
Sildenafil and Exercise Capacity in Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 30
- Registration Number
- NCT00599235
- Locations
- 🇬🇧
University of Edinburgh - Western General Hospital, Edinburgh, United Kingdom
Hydralazine as a Demethylating Agent in Rectal Cancer
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT00575640
Hydralazine as Demethylating Agent in Breast Cancer
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT00575978
Hydralazine Valproate for Ovarian Cancer
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2007-09-21
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 211
- Registration Number
- NCT00533299
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Tlalpan, Mexico
Hydralazine Valproate for Cervical Cancer
- Conditions
- Metastatic Cervical Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 143
- Registration Number
- NCT00532818
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer
- Conditions
- Cervical Cancer
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2006-11-28
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 18
- Registration Number
- NCT00404326
- Locations
- 🇲🇽
National Institute of Cancerologia, Mexico City, Tlalpan, Mexico
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
- Conditions
- Refractory Solid Tumors
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2006-11-28
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 15
- Registration Number
- NCT00404508
- Locations
- 🇲🇽
National Institute of Cancerologia, Mexico City, Tlalpan, Mexico
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
- Conditions
- Locally Advanced Breast Cancer
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2006-11-03
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 43
- Registration Number
- NCT00395655
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Tlalpan, Mexico
Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage
- Conditions
- CVA (Cerebrovascular Accident)Cerebral HemorrhageIntracranial Hemorrhages
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2008-06-26
- Lead Sponsor
- The George Institute
- Target Recruit Count
- 404
- Registration Number
- NCT00226096
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDietary Supplement: L-arginineOther: Head-up tilt.Other: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.